Form 4: Eli Lilly Executive Anat Hakim Acquires Shares and Restricted Stock Units

Sentiment:

SEC Form 4 Filing


Eli Lilly's Executive Vice President, General Counsel, and Secretary, Anat Hakim, acquired 5,815 shares of common stock and 4,904 restricted stock units on February 12, 2024.

Summary

  • Anat Hakim, an Executive Vice President, General Counsel, and Secretary at Eli Lilly & Co, reported a transaction on February 12, 2024.
  • Hakim acquired 5,815 shares of Eli Lilly common stock at a price of $737.26 per share.
  • Additionally, Hakim acquired 4,904 restricted stock units, each representing a contingent right to receive one share of Eli Lilly common stock.
  • These restricted stock units are set to vest on February 1, 2025.
  • Following these transactions, Hakim directly owns 30,479 shares of common stock and 4,904 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, which is generally positive as it indicates executive alignment with company performance. There are no negative implications.

Positives

  • The acquisition of shares by a high-ranking executive could be seen as a positive signal of confidence in the company's future performance.
  • The acquisition of restricted stock units aligns the executive's interests with the long-term success of the company.

Industry Context

This is a routine filing related to executive compensation and stock ownership, which is common in publicly traded companies like Eli Lilly.

Comparison to Industry Standards

  • Executive stock acquisitions and grants of restricted stock units are standard practice in the pharmaceutical industry, used to incentivize and retain key personnel.
  • Companies like Pfizer, Merck, and AbbVie also regularly report similar transactions by their executives.
  • The vesting period of the restricted stock units is typical, usually ranging from one to three years.

Stakeholder Impact

  • The transaction may have a minor positive impact on shareholder sentiment, as it indicates executive confidence in the company.
  • The vesting of restricted stock units could incentivize the executive to focus on long-term value creation.

Key Dates

DateDescription
02/12/2024Date of the stock and restricted stock unit acquisition.
02/01/2025Vesting date for the restricted stock units.
02/14/2024Date the form was signed.

Keywords

Eli Lilly, Anat Hakim, stock acquisition, restricted stock units, executive transaction, insider trading, SEC Form 4

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.